In the years 2011–2015, the anti-fibrotic drug pirfenidone (inhibitor of TGF-β, TNF α and of PDGF) and the triple kinase inhibitor nintedanib (inhibitor of PDGF, VEGF, and FGF) have both been approved for treatment of Idiopathic Pulmonary Fibrosis (IPF) in the European Union as well as in the United States. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.